C
CURE
Building the "one-stop-shop" platform for healthcare
About CURE
CURE operates within the health technology sector, specifically targeting the digital transformation of local pharmacies. The company provides a B2B solution aimed at integrating brick-and-mortar pharmacies into the digital economy. At the core of its offering is the CURE Order Platform, which functions as an AI-powered Co-Pilot. This platform enables pharmacies to connect with a network of third-party service providers, thereby streamlining their operational workflows.
The business model appears to be centered on facilitating revenue growth for its pharmacy clients. By integrating with various services, the platform allows pharmacies to manage their business operations more efficiently and access new market channels. This suggests a focus on optimizing backend processes, from inventory management to order fulfillment, through a centralized digital hub. The clients are independent and local pharmacies seeking to modernize their services and compete in an increasingly digital marketplace.
The service is designed to bridge the gap between traditional pharmacy operations and modern e-commerce expectations. By using the CURE platform, pharmacies can expand their service offerings and enhance their delivery capabilities. This system aims to improve how pharmacies manage their business, from handling prescriptions to coordinating with delivery services, ultimately enhancing the end-customer experience without the pharmacy needing to build the digital infrastructure from scratch.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2022 | $17M | $66M | Abstract Ventures · Breega · J12 Ventures · Pi Labs | ↗ |
| SEED✓Equity / VC | Feb 2022 | $4.4M | $18M | Abstract Ventures · J-Ventures · Craft Ventures · J12 Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for CURE is 1.8K monthly website visits, up 119.5% over the last three months. CURE's team declined 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Abstract Ventures
J-Ventures
Craft Ventures
J12 Ventures
Series A2 investors entered at this stage
Breega
Pi Labs
Other known investors1 additional known investor
Adam Jafer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CURE on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CURE’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






